glp 1 available in canada approves first generic GLP-1 drug G7 3 million Canadians use GLP-1

Only 32% of patients in the Januvia group were able to achieve this result

Clinical Oversight & Follow-Up Every patient receives: Routine monitoring of blood pressure and overall response Optional follow-up via telehealth consultation Ongoing adjustments to improve tolerability and maximize benefit This holistic, physician-guided model ensures that adverse effects remain manageable and that long-term outcomes support both safety and satisfaction

Could medications such as semaglutide (Ozempic), liraglutide (Victoza), or tirzepatide (Mounjaro) influence arrhythmia risk beyond glucose lowering

Prescription weight-management medications may be used (in combination with a reduced-calorie diet and increased physical activity) for people with one of the following conditions: A body mass index (BMI) of 30 or higher A BMI of 27 or higher with a weight-related condition, such as high blood pressure or type 2 diabetes GLP-1s and weight-management medications may also be prescribed for reasons outside of this list

Further research by Sikiric et al

This is why early diagnosis and treatment matter